Rating History for Neurocrine Bio. (NBIX) by Guggenheim
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 10/5/2026 | Delma Caiati | New Coverage | Buy (N/A) |
207.00 (N/A) |
143.18 (136.98) |
-4.33% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 10/5/2026 | Delma Caiati | New Coverage | Buy (N/A) |
207.00 (N/A) |
143.18 (136.98) |
-4.33% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||